INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease
13 avr. 2022 16h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, April 13, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
11 avr. 2022 08h00 HE
|
INmune Bio, Inc.
Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors,...
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit
04 avr. 2022 09h00 HE
|
INmune Bio, Inc.
INKmune™, unlike IL15 and other NK-activating cytokines, upregulates all mitochondrial survival proteins and more than 40 nutrient receptors on the NK cell to increase survival Boca Raton, Florida,...
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
30 mars 2022 08h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Spotlights Key Findings in Presentations at AD/PD™ 2022
25 mars 2022 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, March 25, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness...
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 - International Conference on Alzheimer's and Parkinson's Diseases
15 mars 2022 08h00 HE
|
INmune Bio, Inc.
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of Targeting Neuroinflammation and Glial Activation with XPro™ for Treatment of Alzheimer’s Disease ...
INmune Bio, Inc. to Participate in the 32nd Annual Oppenheimer Healthcare Conference and the 2022 Maxim Group Virtual Growth Conference
14 mars 2022 16h30 HE
|
INmune Bio, Inc.
Boca Raton, FL, March 14, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system...
INmune Bio, Inc. Announces Fourth Quarter and Full Year 2021 Results and Provides Business Update
03 mars 2022 16h00 HE
|
INmune Bio, Inc.
Cash of $74.8 million on December 31, 2021 Company to host conference call today, March 3, at 4:30pm ET Boca Raton, Florida, March 03, 2022 (GLOBE NEWSWIRE) -- INmune Bio,...
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
23 févr. 2022 09h00 HE
|
INmune Bio, Inc.
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Feb. 23, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
08 févr. 2022 09h00 HE
|
INmune Bio, Inc.
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...